Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2011-03-08
2011-03-08
Wen, Sharon (Department: 1644)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S387100, C530S387900, C530S388100
Reexamination Certificate
active
07902340
ABSTRACT:
The present invention concerns an antibody specific for human ALK (Anaplastic Lymphoma Kinase), in particular a scFv, a nucleic acid sequence encoding it, its production and its use as a pharmaceutical or for diagnostic purposes. Said antibody is suitable for the local treatment of tumors, in particular glioblastoma.
REFERENCES:
patent: 5529925 (1996-06-01), Morris et al.
patent: 5770421 (1998-06-01), Morris et al.
patent: 5991244 (1999-11-01), Kondo et al.
patent: 6174674 (2001-01-01), Morris et al.
patent: 6451997 (2002-09-01), Morris et al.
patent: 6696548 (2004-02-01), Morris et al.
patent: 7528109 (2009-05-01), Wellstein
patent: 7608264 (2009-10-01), Wellstein
patent: 2001/0021505 (2001-09-01), Morris et al.
patent: 2002/0034768 (2002-03-01), Wellstein
patent: 2009/0232815 (2009-09-01), Wellstein
patent: 2010/0111964 (2010-05-01), Wellstein
patent: 1479694 (2004-11-01), None
patent: 95/15331 (1995-06-01), None
patent: 01/96394 (2001-12-01), None
patent: 03/097697 (2003-11-01), None
patent: 2006/020684 (2006-02-01), None
Rudikoff et al Proc Natl Acad Sci USA 1982 vol. 79 p. 1979.
MacCallum et al. J. Mol. Biol. (1996) 262, 732-745.
Pascalis et al. The Journal of Immunology (2002) 169, 3076-3084.
Casset et al. BBRC 2003, 307:198-205.
Vajdos et al. J. Mol. Biol. (2002) 320, 415-428.
Chen et al. J. Mol. Bio. (1999) 293, 865-881.
Wu et al. J. Mol. Biol. (1999) 294, 151-162.
Padlan et al. PNAS 1989, 86:5938-5942.
Lamminmaki et al. JBC 2001, 276:36687-36694.
Klimka et al. British Journal of Caner 2000, 83:252-260.
Beiboer et al. J. Mol. Biol. 2000, 296:833-849.
Barbas et al. PNAS 1995, 92:2529-2533.
Lederman et al. Molecular Immunology 28: 1171-1181, 1991.
Li et al. PNAS 77: 3211-3214, 1980.
Houghten et al. New Approaches to Immunization, Vaccines 86, Cold Spring Harbor Laboratory, p. 21-25, 1986).
Bernard-Pierrot et al. JBC 2002, 277:32071-32077.
Stoica et al. JBC 2001, 276:16772-16779.
Auf der Maur, Adrian et al., “Antigen-independent selection of stable intracellular single-chain antibodies,” FEBS Letters, vol. 508:407-412 (2001).
Auf der Maur, Adrian et al., “Antigen-independent selection of intracellular stable antibody frameworks,” Methods, vol. 34:215-224 (2004).
Auf der Maur, Adrian et al., “Direct in Vivo Screening of Intrabody Libraries Constructed on a Highly Stable Single chain Framework,” The Journal of Biological Chemistry, vol. 277(47):45075-45085 (2002).
Bai, Ren-Yuan et al., “Nucleophosmin-anaplastic lymphoma kinase associated with anaplastic large-cell lymphoma activates the phosphatidylinositol 3-kinase/Akt antiapoptotic signaling pathway,” Blood, vol. 96(13):4319-4327 (2000).
Barbas, Shana M. et al., “Recognition of DNA by Synthetic Antibodies,” J. Am. Chem. Soc., vol. 116:2161-2162 (1994).
Bowden, Emma T. et al., “Anti-apoptotic Signaling of Pleiotrophin through Its Receptor, Anaplastic Lymphoma Kinase,” The Journal of Biological Chemistry, vol. 277(39):35862-35868 (2002).
Chothia, Cyrus et al., “Canonical Structures for the Hypervariable Regions of Immunoglobulins,” J. Mol. Biol., vol. 196:901-917 (1987).
Chothia, Cyrus et al., “Domain Association in Immunoglobulin Molecues. The Packing of Variable Domains,” J. Mol. Biol., vol. 186:651-663 (1985).
Choudhuri, Rangana et al., “An Angiogenic Role for the Neurokines Midkine and Pleiotrophin in Tumorigenesis,” Cancer Research, vol. 57:1814-1819 (1997).
Clackson, Tim et al., “Making antibody fragments using phage display libraries,” Nature, vol. 352:624-628 (1991).
Czubayko, Frank et al., “Melanoma angiogenesis and metastasis modulated by ribozyme targeting of the secreted growth factor pleiotrophin,” Proc. Natl. Acad. Sci. USA, vol. 93:14753-14758 (1996).
De Juan, Carmen et al., “Genomic organization of a novel glycosylphosphatidylinositol MAM gene expressed in human tissues and tumors,” Oncogene, vol. 21:3089-3094 (2002).
Delsol, Georges et al., “A New Subtype of Large B-Cell Lymphoma Expressing the ALK Kinase and Lacking the 2;5 Translocation,” Blood, vol. 89(5):1483-1490 (1997).
Dirks, Willy G. et al., “Expression and Functional Analysis of the Anaplastic Lymphoma Kinase (ALK) Gene in Tumor Cell Lines,” Int. J. Cancer, vol. 100:49-56 (2002).
Ditzel, Henrik J. et al., “Determinants of Polyreactivity in a Large Panel of Recombinant Human Antibodies from HIV-1 Infection,” The Journal of Immunology, vol. 157:739-749 (1996).
Duyster, Justus et al., “Translocations involving anaplastic lymphoma kinase (ALK),” Oncogene, vol. 20:5623-5637 (2001).
Ergin, Melek et al., “Inhibition of tyrosine kinase activity induces caspase-dependent apoptosis in anaplastic large cell lymphoma with NPM-ALK (p80) fusion protein,” Experimental Hematology, vol. 29:1082-1090 (2001).
Fang, Wenjing et al., “Pleiotrophin Stimulates Fibroblasts and Endothelial and Epithelial Cells and Is Expressed in Human Cancer,” The Journal of Biological Chemistry, vol. 267(36):25889-25897 (1992).
Fiorani, C. et al., “Primary systemic anaplastic large-cell lymphoma (CD30+): advances in biology and current therapeutic approaches,” Clinical Lymphoma, vol. 2(1):29-37 (2001).
Iwahara, Toshinori et al., “Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system,” Oncogene, vol. 14:439-449 (1997).
Kutok, Jeffery L. et al., “Molecular Biology of Anaplastic Lymphoma Kinase-Positive Anaplastic Large-Cell Lymphoma,” Journal of Clinical Oncology, vol. 20(17):3691-3702 (2002).
Ladanyi, Marc et al., “Aberrant ALK Tyrosine Kinase Signaling. Different Cellular Lineages, Common Oncogenic Mechanisms?” American Journal of Pathology, vol. 157(2):341-345 (2000).
Lamant, Laurence et al., “Expression of the ALK Tyrosine Kinase Gene in Neuroblastoma,” American Journal of Pathology, vol. 156(5):1711-1721 (2000).
Li, Xiao-Qiu et al., “Expression of Anaplastic Lymphoma Kinase in Soft Tissue Tumors: An Immunohistochemical and Molecular Study of 249 Cases,” Human Pathology, vol. 35(6):711-721 (2004).
Loren, Christina E. et al., “Identification and characterization of DAIk: a novel Drosophila melanogaster RTK which drives ERK activation in vivo,” Genes Cells, vol. 6(6):531-544 (2001).
Miyake, Izumi et al., “Activation of anaplastic lymphoma kinase is responsible for hyperphosphorylation of ShcC in neuroblastoma cell lines,” Oncogene, vol. 21:5823-5834 (2002).
Morris, Stephan W. et al., “ALK, the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkin's lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK),” Oncogene, vol. 14:2175-2188 (1997).
Morris, Stephan W. et al., “ALK+ CD30+ Lymphomas: A Distinct Molecular Genetic Subtype of non-Hodgkin's Lymphoma,” British Journal of Hematology, vol. 113:275-295 (2001).
O'Brien, Tim et al., “The Angiogenic Factor Midkine Is Expressed in Bladder Cancer, and Overexpression Correlates with a Poor Outcome in Patients with Invasive Cancers,” Cancer Research, vol. 56:2515-2518 (1996).
Padlan, Eduardo A. et al., “Anatomy of the Antibody Molecule,” Molecular Immunology, vol. 31(3):169-217 (1994).
Portolano, Stefano et al., “Lack of Promiscuity in Autoantigen-Specific H and L Chain Combinations as Revealed by Human H and L Chain ‘Roulette’,” The Journal of Immunology, vol. 150(3):880-887 (1993).
Powers, Ciaran et al., “Pleiotrophin Signaling through Anaplastic Lymphoma Kinase Is Rate-limiting for Glioblastoma Growth,” The Journal of Biological Chemistry, vol. 277(16):14153-14158 (2002).
Pulford, Karen et al., “Anaplastic lymphoma kinase proteins and malignancy,” Current Opinion in Hematology, vol. 81:231-236 (2001).
Pulford, K. et al., “Anaplastic Lymphoma Kinase Pro
Auf Der Maur Adrian
Barberis Alcide
Lichtlen Peter
Delenex Therapeutics AG
Lathrop & Gage LLP
Velema, Esq. James H.
Wen Sharon
Wilkins Andrew T.
LandOfFree
Antibodies binding to the extracellular domain of the... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antibodies binding to the extracellular domain of the..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibodies binding to the extracellular domain of the... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2725512